导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.81% | 1538/4773 |
| 近一周 | -1.19% | 1790/5465 |
| 近一月 | -8.19% | 4814/5421 |
| 近一季 | -18.16% | 4700/5231 |
| 近半年 | -0.63% | 1534/4920 |
| 近一年 | 7.85% | 1412/4394 |
| 近两年 | 112.62% | 500/2954 |
| 近三年 | 67.82% | 376/2253 |
| 成立以来 | 121.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.84% 1985/4961 |
34.99% 933/5312 |
- - |
- - |
| 2025 | 49.43% 484/4813 |
-1.43% 2665/3635 |
3.31% 1058/4076 |
47.93% 416/4524 |
-0.80% 2647/4813 |
| 2024 | 14.10% 1076/3463 |
-3.50% 1512/2808 |
-6.18% 1878/3014 |
27.79% 207/3129 |
-1.39% 1680/3463 |
| 2023 | -17.23% 1723/2656 |
2.19% 1414/2280 |
-6.62% 1676/2385 |
-8.41% 1697/2515 |
-5.30% 1315/2655 |
| 2022 | -27.04% 1452/2207 |
-18.62% 1361/1919 |
5.67% 846/2016 |
-17.22% 1562/2113 |
2.49% 920/2208 |
| 2021 | 17.31% 237/1822 |
-4.24% 852/1255 |
25.92% 81/1330 |
-5.34% 797/1466 |
2.78% 518/1822 |
| 2020 | 69.17% 78/1250 |
4.93% 57/1028 |
29.32% 79/1067 |
7.97% 749/1164 |
15.46% 205/1184 |
| 2019 | - - |
- - |
- - |
- - |
9.65% 212/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 永赢创业板指数发起式A VS. 长安沪深300非周期A(740101) |